⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INKT News
MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
globenewswire.com
INKT
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
globenewswire.com
INKT
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
globenewswire.com
INKT
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
globenewswire.com
INKT
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
globenewswire.com
INKT